14-Oct-2026
Sutro Biopharma highlights STRO-004 safety and dual-payload STRO-227 at World ADC Conference
Market Chameleon (Tue, 13-Oct 7:09 AM ET)
Market Chameleon (Mon, 12-Oct 7:53 AM ET)
Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference
Globe Newswire (Mon, 12-Oct 8:00 AM ET)
Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development
Globe Newswire (Tue, 29-Sep 8:00 AM ET)
Globe Newswire (Wed, 12-Aug 7:00 AM ET)
Sutro Biopharma Advances STRO-004 with First Patients Dosed in Pioneering Phase 1 Study
Market Chameleon (Thu, 4-Dec 5:03 AM ET)
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Sutro Biopharma trades on the NASDAQ stock market under the symbol STRO.
As of October 14, 2026, STRO stock price declined to $10.52 with 462,221 million shares trading.
STRO has a beta of 2.47, meaning it tends to be more sensitive to market movements. STRO has a correlation of 0.11 to the broad based SPY ETF.
STRO has a market cap of $174.29 million. This is considered a Micro Cap stock.
Last quarter Sutro Biopharma reported $10 million in Revenue and -$2.33 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$.11.
In the last 3 years, STRO traded as high as $61.30 and as low as $5.23.
The top ETF exchange traded funds that STRO belongs to (by Net Assets): VTI, IWM, VXF, VTWO, FESM.
STRO has outperformed the market in the last year with a return of +31.5%, while the SPY ETF gained +17.4%. However, in the most recent history, STRO shares have underperformed the stock market with its stock returning -59.6% in the last 3 month period and -34.7% for the last 2 week period, while SPY has returned +2.6% and +0.9%, respectively.
STRO support price is $10.34 and resistance is $11.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that STRO shares will trade within this expected range on the day.
